SCHEMBL4672853

SCHEMBL4672853

COc1cccc(Sc2cc(C(=O)C=C(O)c3nc[nH]n3)co2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
NPC1 O15118 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PTPN11 Q06124 1/20 0.34
NOTUM Q6P988 1/20 0.34
CHEK2 O96017 1/20 0.34
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
MTNR1A P48039 2/20 0.33
MTNR1B P49286 2/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
MAPK1 P28482 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
TERT O14746 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671258 0.89 NR4A2 (0.36) ALDH1A1HPGDNPC1MEN1KMT2A
SCHEMBL4671724 0.87 MEN1 (0.35) ALDH1A1HPGDMEN1KMT2APTPN11
SCHEMBL4674659 0.84 ALDH1A1 (0.35) ALDH1A1NPC1MEN1KMT2ANOTUM
SCHEMBL4676271 0.84 EDNRA (0.38) EDNRAALDH1A1NPC1MEN1KMT2A
SCHEMBL4672707 0.84 PTPN11 (0.46) EDNRAALDH1A1HPGDNPC1MEN1
SCHEMBL4675504 0.83 ALDH1A1 (0.31) ALDH1A1MEN1KMT2AMAPTMAPK1
SCHEMBL4671161 0.82 HPGD (0.36) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL4675521 0.82 HAO1 (0.34) ALDH1A1HPGDNPC1MEN1KMT2A
SCHEMBL4673485 0.82 LMNA (0.38) ALDH1A1HPGDNPC1MEN1KMT2A
SCHEMBL4676163 0.81 HAO1 (0.34) MEN1KMT2AMAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 EDNRA 1157/4885ALDH1A1 980/4885HPGD 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.